Amorphous drugs and dosage forms

Holger Grohganz; K. Löbmann; P. Priemel; Katrine Birgitte Tarp Jensen; K. Graeser; C. Strachan; T. Rades

Amorphous drugs and dosage forms

Holger Grohganz, K. Löbmann, P. Priemel, Katrine Birgitte Tarp Jensen, K. Graeser, C. Strachan, T. Rades

36 Citations (Scopus)

Abstract

The transformation to an amorphous form is one of the most promising approaches to address the low solubility of drug compounds, the latter being an increasing challenge in the development of new drug candidates. However, amorphous forms are high energy solids and tend to recry stallize. New formulation principles are needed to ensure the stability of amorphous drug forms. The formation of solid dispersions is still the most investigated approach, but additional approaches are desirable to overcome the shortcomings of solid dispersions. Spatial separation by either coating or the use of micro-containers has shown potential to prevent or delay recrystallization. Another recent approach is the formation of co-amorphous mixtures between either two drugs or one drug and one low molecular weight excipient. Molecular interactions between the two molecules provide an energy barrier that has to be overcome before single molecules are available for the formation of crystal nuclei, thus stabilizing the amorphous form.

Original language	English
Journal	Journal of Drug Delivery Science and Technology
Volume	23
Issue number	4
Pages (from-to)	403-408
Number of pages	6
ISSN	1773-2247
Publication status	Published - 1 Jul 2013

Cite this

@article{dcda7259ebea4b1882bafeec5d17f63b,

title = "Amorphous drugs and dosage forms",

abstract = "The transformation to an amorphous form is one of the most promising approaches to address the low solubility of drug compounds, the latter being an increasing challenge in the development of new drug candidates. However, amorphous forms are high energy solids and tend to recry stallize. New formulation principles are needed to ensure the stability of amorphous drug forms. The formation of solid dispersions is still the most investigated approach, but additional approaches are desirable to overcome the shortcomings of solid dispersions. Spatial separation by either coating or the use of micro-containers has shown potential to prevent or delay recrystallization. Another recent approach is the formation of co-amorphous mixtures between either two drugs or one drug and one low molecular weight excipient. Molecular interactions between the two molecules provide an energy barrier that has to be overcome before single molecules are available for the formation of crystal nuclei, thus stabilizing the amorphous form.",

author = "Holger Grohganz and K. L{\"o}bmann and P. Priemel and Jensen, {Katrine Birgitte Tarp} and K. Graeser and C. Strachan and T. Rades",

year = "2013",

month = jul,

day = "1",

language = "English",

volume = "23",

pages = "403--408",

journal = "Journal of Drug Delivery Science and Technology",

issn = "1773-2247",

publisher = "Elsevier",

number = "4",

}

TY - JOUR

T1 - Amorphous drugs and dosage forms

AU - Grohganz, Holger

AU - Löbmann, K.

AU - Priemel, P.

AU - Jensen, Katrine Birgitte Tarp

AU - Graeser, K.

AU - Strachan, C.

AU - Rades, T.

PY - 2013/7/1

Y1 - 2013/7/1

N2 - The transformation to an amorphous form is one of the most promising approaches to address the low solubility of drug compounds, the latter being an increasing challenge in the development of new drug candidates. However, amorphous forms are high energy solids and tend to recry stallize. New formulation principles are needed to ensure the stability of amorphous drug forms. The formation of solid dispersions is still the most investigated approach, but additional approaches are desirable to overcome the shortcomings of solid dispersions. Spatial separation by either coating or the use of micro-containers has shown potential to prevent or delay recrystallization. Another recent approach is the formation of co-amorphous mixtures between either two drugs or one drug and one low molecular weight excipient. Molecular interactions between the two molecules provide an energy barrier that has to be overcome before single molecules are available for the formation of crystal nuclei, thus stabilizing the amorphous form.

AB - The transformation to an amorphous form is one of the most promising approaches to address the low solubility of drug compounds, the latter being an increasing challenge in the development of new drug candidates. However, amorphous forms are high energy solids and tend to recry stallize. New formulation principles are needed to ensure the stability of amorphous drug forms. The formation of solid dispersions is still the most investigated approach, but additional approaches are desirable to overcome the shortcomings of solid dispersions. Spatial separation by either coating or the use of micro-containers has shown potential to prevent or delay recrystallization. Another recent approach is the formation of co-amorphous mixtures between either two drugs or one drug and one low molecular weight excipient. Molecular interactions between the two molecules provide an energy barrier that has to be overcome before single molecules are available for the formation of crystal nuclei, thus stabilizing the amorphous form.

UR - http://www.scopus.com/inward/record.url?scp=84881580992&partnerID=8YFLogxK

M3 - Review

AN - SCOPUS:84881580992

SN - 1773-2247

VL - 23

SP - 403

EP - 408

JO - Journal of Drug Delivery Science and Technology

JF - Journal of Drug Delivery Science and Technology

IS - 4

ER -

Amorphous drugs and dosage forms

Abstract

Other files and links

Fingerprint

Cite this